Laekna, Inc.

來凱醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2105)

VOLUNTARY ANNOUNCEMENT
COMPLETION OF A SUCCESSFUL PHASE I SAD STUDY OF LAE102 FOR THE TREATMENT OF OBESITY

This announcement is made by Laekna, Inc. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the "**Board**") of directors of the Company (the "**Directors**") is pleased to announce that the Group has successfully completed the phase I single ascending dose study (the "**SAD Study**") of LAE102 for the treatment of obesity. The SAD Study enrolled a total of 64 healthy subjects with an average BMI of 23.2±2.2 kg/m^2, including 5 intravenous cohorts and 3 subcutaneous cohorts. The positive outcomes of the SAD Study results have established a solid foundation for the coming phase I multiple ascending dose study (the "**MAD Study**") in China as well as the phase I clinical study in collaboration with Eli Lilly & Company ("**Lilly**") in the U.S.

The SAD Study data of LAE102 analyzed to date demonstrated an encouraging safety and tolerability profile, with no serious adverse events and no discontinuations due to adverse events. All treatment emergent adverse events reported to date were very well tolerated, with the majority of them being reported as mild (grade 1) lab test abnormality without any clinical symptoms or signs. There is no reported case of diarrhea. Obvious target engagements and expected pharmacodynamic biomarker changes have been observed. Single doses of LAE102 resulted in significant and sustained increasing in activin A level, indicating a robust target engagement. The duration of target engagement correlated to the dose level. The detailed study results will be presented in a scientific conference as soon as possible.

The positive SAD Study results support continuing the investigation of LAE102 for the treatment of obesity. The Group plans to initiate the MAD Study in the first quarter of 2025 and to work closely with Lilly to commence the phase I clinical study in U.S. as soon as possible. The MAD Study is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of LAE102,

administered subcutaneously, in 60 overweight/obese subjects. The Group aims to bring this precision therapy to overweight and obese patients who are in need of novel treatment options for achieving quality weight control.

About LAE102

LAE102 is an internally discovered monoclonal antibody selectively targeting ActRIIA, a receptor that plays an important role in muscle regeneration and lipid metabolism. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass. In combination with GLP1R agonist, LAE102 can further reduce fat mass and significantly regain the lean mass loss induced by GLP1R agonist. This positions LAE102 as a promising drug candidate for achieving quality weight control.

RISK WARNING

LAE102 MAY ULTIMATELY NOT BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.

By Order of the Board
Laekna, Inc.
Dr. LU Chris Xiangyang
Chairman

Hong Kong, January 13, 2025

As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.